Pharmacokinetics of ketorolac loaded to polyethylcyanoacrylate nanoparticles using UPLC MS/MS for its determination in rats

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 173-178

  Radwan, M A ^a   AlQuadeib, B T ^a   Aloudah, N M ^a   Aboul Enein, H Y ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Furbiprofen; Ketorolac; Nanoparticles; Pharmacokinetics; Polyethylcyanoacrylate; UPLC MS MS

Indexed keywords

KETOROLAC; KETOROLAC TROMETAMOL; NANOPARTICLE; POLY(ETHYL 2 CYANOACRYLATE);

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYANOACRYLATES; KETOROLAC; MALE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; RATS; RATS, WISTAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 77955983533     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.035     Document Type: Article

References (33)

1. Alsarra I.A., Bosela A.A., Ahmed S.M., Mahrous G.M. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur. J. Pharm. Biopharm. 2005, 59:485-490.
2. Barratt G.M. Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today 2000, 3:163-171.
3. Bhaskaran S., Suresh S. Biodegradable microspheres of ketorolac tromethamine for parenteral administration. J. Microencapsulation 2004, 21:743-750.
4. Brown C.R., Moodie J.E., Wild V.M., Bynum L.J. Comparison of intravenous ketorolac tromethamine and morphine sulfate in the treatment of postoperative pain. Pharmacotherapy 1990, 10:116S-121S.
5. Corelli R.L., Gericke K.R. Renal insufficiency associated with intramuscular administration of ketorolac tromethamine. Ann. Pharmacother. 1993, 27:1055-1057.
6. Couvreur P., Kante B., Roland M., Guiot P., Bauduin P., Speiser P. Polycyanoacrylate nanoparticles as potential lysomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 1979, 31:311-332.
7. Couvreur P., Kante B., Lenaerts V., Scailteur V., Roland M., Speiser P. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J. Pharm. Sci. 1980, 69:199-202.
8. Genç L., Jalvand E. Preparation and in vitro evaluation of controlled release hydrophilic matrix tablets of ketorolac tromethamine using factorial design. Drug Deliv. Ind. Pharm. 2008, 34:903-910.
9. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York, pp. 407-417. second ed.
10. Goodman E. Use of ketorolac in sickle cell disease and vasoocclusive crisis. Lancet 1991, 338:641-642.
11. Green D., Klement P., Liao P., Weitz J. Interaction of low molecular weight heparin with ketorolac. J. Lab. Clin. Med. 1996, 127:583-587.
12. Gupta A.K., Sumit Madan A.K., Majumdar D.K., Maitra A. Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies. Int. J. Pharmacol. 2000, 209:1-14.
13. Hyers T.M., Tricomi S.M., Liao J.J. Inhibition of some human neutrophil functions by the cyclooxygenase inhibitor ketorolac tromethamine. J. Leukoc. Biol. 1992, 51:490-495.
14. Ilum L., Jones P.D.E., Baldwin R.W., Davis S.S. Tissue distribution of poly (hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal anribodies in mice bearing human tumer xenografts. J. Pharmacol. Exp. Ther. 1984, 230:733-736.
15. Krauel K., Pitaksuteepong T., Davies N.D., Rades T. Entrapment of bioactive molecules in poly(alkylcyanoacrylate) nanoparticles. Am. J. Drug Deliv. 2004, 2:251-258.
16. Kreuter J., Hartmann H.R. Comparative study on the cytostatic effects and tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in Sarcoma 180-bearing mice. Oncology 1983, 40:363-366.
17. Letchford K., Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 2007, 65:259-269.
18. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal. Chem. 1998, 70:882-889.
19. Radwan M.A. Enhancement of insulin-loaded polyisobutylcyanoacrylate nanospheres absorption by sodium cholate after oral and subcutaneous administrations in diabetic rats. Drug Dev. Ind. Pharm. 2001, 27:981-989.
20. Radwan M.A. Preparation and in vivo evaluation of parenteral metoclopramide-loaded poly(alkylcyanoacrylate) nanospheres in rats. J. Microencapsulation 2001, 18:467-477.
21. Radwan M.A., Aboul-Enein H.Y. The effect of various oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J. Microencapsulation 2002, 19:225-235.
22. Rokhade A.P., Agnihotri S.A., Patil S.A., Mallikarjuna N.N., Kulkarni P., Aminabhavi T.M. Semi-interpenetrating polymer network microspheres of gelatin and sodium carboxymethyl cellulose for controlled release of ketorolac tromethamine. Carbohydr. Polym. 2006, 65:243-252.
23. Rusy L.M., Houck C.S., Sullivan L.J., Ohlms L.A., Jones D.T., McGill T.J., Berde C.B. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth. Analg. 1995, 80:226-229.
24. Sinha V.R., Kumar R.V., Singh G. Ketorolac tromethamine formulations: an overview. Expert Opin. Drug Deliv. 2009, 6:961-975.
25. Sinha V.R., Trehan A. Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres. Drug Deliv. 2005, 12:133-139.
26. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
27. Stella B., Arpicco S., Rocco F., Marsaud V., Renoir J.M., Cattel L., Couvreur P. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int. J. Pharm. 2007, 344:71-77.
28. United States Pharmacopoeia XXXIII 2003, The United States Pharmacopeia Convention, Rockville, MD, p. 2439.
29. US Food and Drug Administration Guidance for Industry. Bioanalytical Method Validation 2001, May, (accessed May 2004). http://www.fda.gov/downloads/Drugs/Guidance%20ComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
30. Vauthier C., Dubernet C., Fattal E., Pinto-Alphandary P., Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 2003, 55:519-548.
31. Vauthier C., Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res. 2008, 26:1025-1058.
32. Vauthier C., Cabane B., Labarre D. How to concentrate nanoparticles and avoid aggregation?. Eur. J. Pharm. Biopharm. 2008, 69:466-475.
33. Yee J.P., Koshiver J.E., Allbon C., Brown C.R. Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery. Clin. Pharmacol. Ther. 1986, 237:253-261.